TM-233

TM-233 is an inhibitor of the JAK/STAT and NF-κB signaling pathways, exhibiting significant antitumor activity. TM-233 reduces the expression of the anti-apoptotic protein Mcl-1 by inhibiting the phosphorylation of JAK2 and STAT3, and regulates its transcription by directly binding to the Mcl-1 gene promoter. Additionally, TM-233 prevents the translocation of NF-κB from the cytoplasm to the nucleus by inhibiting its DNA-binding activity, thereby reducing nuclear NF-κB expression. TM-233 shows potential in overcoming Bortezomib (HY-10227) resistance and can be applied in research related to multiple myeloma[1].

Product Specifications

CAS Number

[1103745-28-3]

UNSPSC

12352005

Target

Bcl-2 Family; JAK; NF-κB; STAT

Type

Reference compound

Related Pathways

Apoptosis; Epigenetics; JAK/STAT Signaling; NF-κB; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tm-233.html

Smiles

CC(OC(C1=CC=C(C=C1)OC(C)=O)C2=C3C=CC=CC3=CC4=CC=CC=C24)=O

Molecular Formula

C25H20O4

Molecular Weight

384.42

References & Citations

[1]Sagawa M, et al. TM-233 Exerts Anti-Myeloma Activity and Overcomes Bortezomib-Resistance In Human Multiple Myeloma Cells By Targeting NF-κB and JAK/STAT Dual-Signaling Pathways[J]. Blood, 2013, 122 (21) : 4427.